Clinical Of Plain Balloon Dilatation Combined Stent Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower Extremity
- Conditions
- IschemiaAtherosclerosis
- Interventions
- Device: balloon and StentDevice: endovascular debulking and DCB
- Registration Number
- NCT05158257
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Brief Summary
This is a Prospective randomized controlled study to evaluate the difference of safety,effectiveness between endovascular debulking combined drug-coated balloon and balloon dilatation combined stent angioplasty in treatment of femoral-popliteal artery lesions.
- Detailed Description
Prospective randomized controlled study to evaluate the difference of safety,effectiveness between endovascular debulking combined drug-coated balloon and balloon dilatation combined stent angioplasty in treatment of femoral-popliteal artery lesions. Patients with femoral-popliteal artery lesions in our department were randomly assigned to the endovascular debulking combined drug-coated balloon group and balloon dilatation combined with stent angioplasty group. Compare the ischemic improvement rate (limb salvage rate, postoperative patency rate) and the complications rate of two different treatments. At the same time, the peri-operative related factors that may affect the end point events, such as preoperative baseline data, lesion characteristics, imaging features, stent fracture, and end point observation indexes were analyzed by regression analysis.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 144
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Intervention: balloon and Stents balloon and Stent plain balloon and Stents group Intervention: debulking and drug coated balloon endovascular debulking and DCB debulking and drug coated balloon group
- Primary Outcome Measures
Name Time Method 12-month Primary Patency Rate 12 months systolic velocity ratio \>2.4 as measured by Duplex ultrasound.
- Secondary Outcome Measures
Name Time Method Major Adverse Events at 12-month Post Procedure 12 months Major adverse events included death, index limb ischemia, index limb amputation, clinically driven target lesion revascularization , and significant embolic events, which were defined as causing end-organ damage.
12-month Limb Salvage Rate 12 months Limb Salvage is defined as the freedom from secondary major amputation
Technical success rate 1 day Technical success was defined as residual stenosis less than 30% by final
freedom from clinically-driven TLR rate 12 months it is defined as the freedom from clinically-driven target lesion revascularization
Trial Locations
- Locations (1)
Gu Yong Quan
🇨🇳Beijing, Beijing, China